Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study.

导出 OA

翻译打印收藏纠错

作者： Naval G,Daver ^[1] ; Pau,Montesinos ^[2] ; Daniel J,DeAngelo ^[3] ; Eunice S,Wang ^[4] ; Nikolaos,Papadantonakis ^[5] ; Elisabetta,Todisco ^[6] ; Kendra L,Sweet ^[7] ; Naveen,Pemmaraju ^[8] ; Andrew A,Lane ^[3] ; Laura,Torres-Miñana ^[2] ; James E,Thompson ^[4] ; Marina Y,Konopleva ^[9] ; Callum M,Sloss ^[10] ; Krystal,Watkins ^[10] ; Gaurav,Bedse ^[10] ; Yining,Du ^[10] ; Kara E,Malcolm ^[10] ; Patrick A,Zweidler-McKay ^[10] ; Hagop M,Kantarjian ^[8]

作者单位： MD Anderson Cancer Center, Houston, Texas, USA. Electronic address: ndaver@mdanderson.org. ^[1] Hospital Universitari i Politècnic La Fe, Valencia, Spain. ^[2] Dana-Farber Cancer Institute, Boston, MA, USA. ^[3] Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. ^[4] University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL, USA. ^[5] Istituto Europeo di Oncologia, Milan, Italy. ^[6] Moffitt Cancer Center, Tampa, FL, USA. ^[7] MD Anderson Cancer Center, Houston, Texas, USA. ^[8] Albert Einstein College of Medicine, Bronx, NY, USA. ^[9] ImmunoGen, Waltham, MA, USA. ^[10]